The impact of Onco type DX® recurrence score of paraffin-embedded core biopsy tissues in predicting response to neoadjuvant chemotherapy in women with breast cancer

Atilla Soran, Rohit Bhargava, Ronald Johnson, Gretchen Ahrendt, Marguerite Bonaventura, Emilia Diego, Priscilla F. McAuliffe, Merida Serrano, Ebru Menekse, Efe Sezgin, Kandace P. McGuire

Research output: Contribution to journalArticle

Abstract

BACKGROUND: Oncotype DX® test is beneficial in predicting recurrence free survival in estrogen receptor positive (ER+) breast cancer. Ability of the assay to predict response to neoadjuvant chemotherapy (NCT) is less well-studied. OBJECTIVE: We hypothesize a positive association between the Oncotype DX® recurrence score (RS) and the percentage tumor response (%TR) after NCT. METHODS: Pre-therapy RS was measured on core biopsies from 60 patients with ER+, HER2.. invasive breast cancer (IBC) who then received NCT. Pre-therapy tumor size was measured using imaging. %TR, partial response (PR; 50%), pathologic complete response (PCR) and breast conserving surgery (BCS) rates were measured. RESULTS: Median RS was 20 (2 69). Median %TR was 42 (0 97)%. PR was observed in 43% of patients. There was no association between %TR and pre-NCT tumor size, age, Nottingham score or nodal status (p 0:05). No statistically significant association with %TR was seen with RS as a categorical or continuous variable (p = 0:21 and 0.7, respectively). Response to NCT improved as ER (p = 0:02) by RT-PCR decreased. Lower ER expression by IHC correlated with response (p = 0:03). CONCLUSIONS: In patients with ER+ IBC receiving NCT, RS did not predict response to NCT using %TR. The benefit of the assay prior to NCT requires further study.

Original languageEnglish (US)
Pages (from-to)65-71
Number of pages7
JournalBreast Disease
Volume36
Issue number2-3
DOIs
StatePublished - 2016
Externally publishedYes

Keywords

  • 21 gene assay
  • breast cancer
  • Estrogen positive
  • neoadjuvant
  • response
  • tumor volume reduction

ASJC Scopus subject areas

  • Medicine(all)
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'The impact of Onco type DX<sup>®</sup> recurrence score of paraffin-embedded core biopsy tissues in predicting response to neoadjuvant chemotherapy in women with breast cancer'. Together they form a unique fingerprint.

  • Cite this

    Soran, A., Bhargava, R., Johnson, R., Ahrendt, G., Bonaventura, M., Diego, E., McAuliffe, P. F., Serrano, M., Menekse, E., Sezgin, E., & McGuire, K. P. (2016). The impact of Onco type DX® recurrence score of paraffin-embedded core biopsy tissues in predicting response to neoadjuvant chemotherapy in women with breast cancer. Breast Disease, 36(2-3), 65-71. https://doi.org/10.3233/BD-150199